

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2023 P 1206-9
Program	Prior Authorization/Notification
Medication	Continuous glucose monitors, sensors and transmitters (all brands)
P&T Approval Date	12/2016, 11/2017, 11/2018, 11/2019, 3/2020, 6/2021, 6/2022, 8/2023
Effective Date	11/1/2023

1. Background:

Continuous glucose monitors may be used by patients with diabetes who require glucose monitoring beyond what can be achieved with a standard blood glucose monitor.

2. Coverage Criteria:

A. Initial Authorization

1. **Continuous glucose monitors, sensors, and transmitters** will be approved for **initial therapy** based on **both** of the following criteria:

a. Diagnosis of diabetes

-AND-

b. **All** of the following:

- (1) Patient is motivated and knowledgeable about use of continuous glucose monitoring
- (2) Patient is adherent to diabetic treatment plan
- (3) Patient participates in ongoing education and support

Authorization will be issued for 12 months.

B. Reauthorization

1. **Continuous glucose monitors, sensors, and transmitters** will be approved for **continuation of therapy** based on the following criterion:

a. Documentation of positive clinical response

Authorization will be issued for 12 months.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.
- Medical Necessity may be in place.

4. References:

1. American Diabetes Association. Diabetes Technology: Standards of Care in Diabetes - 2023. Diabetes Care December 2022, Vol.46, S111-S127
2. Lane AS, Mlynarczyk MA, de Veciana M, et al. Real-time continuous glucose monitoring in gestational diabetes: a randomized controlled trial. Am J Perinatol. 2019 Jul;36(9):891-897.
3. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574.

Program	Prior Authorization/Notification – Continuous Glucose Monitors
Change Control	
12/2016	New program.
11/2017	Annual review. Revised reauthorization criteria.
11/2018	Annual review. Revised authorization timeline, added criteria for insulin use.
5/2/2019	Administrative change. Change Oxford effective date to 6/1/2019.
11/2019	Modified criteria to allow coverage for any type of diabetes.
3/2020	Added requirement that patient is knowledgeable about continuous glucose monitors, participates in education and support, and monitors blood glucose 3 or more times per day.
6/2021	Modified criteria to monitor blood glucose 4 or more times per day and added criteria that patient has inadequate glycemic control despite an intensive diabetes management.
6/2022	Removed requirements that patient is on an intensive insulin regimen, has inadequate glucose control, and regularly monitors blood glucose at least 4 times per day.
8/2023	Annual review. Updated references.